Granahan Investment Management, LLC Beam Therapeutics Inc. Transaction History

Granahan Investment Management, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$30.15 - $48.79 $833,737 - $1.35 Million	-27,653 Reduced 16.88%	136,137 $4.17 Million
Q4 2022 Feb 14, 2023	BUY	$36.73 - $51.6 $1.96 Million - $2.75 Million	53,355 Added 48.31%	163,790 $6.41 Million
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $1.17 Million - $2.07 Million	29,507 Added 36.46%	110,435 $5.26 Million
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $815,148 - $1.7 Million	-27,299 Reduced 25.22%	80,928 $3.13 Million
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $1.33 Million - $2.04 Million	24,835 Added 29.78%	108,227 $6.2 Million
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $506,612 - $737,798	-7,448 Reduced 8.2%	83,392 $6.65 Million
Q3 2021 Nov 15, 2021	SELL	$84.37 - $133.6 $985,694 - $1.56 Million	-11,683 Reduced 11.4%	90,840 $7.9 Million
Q2 2021 Aug 16, 2021	BUY	$64.12 - $128.71 $380,359 - $763,507	5,932 Added 6.14%	102,523 $13.2 Million
Q1 2021 May 17, 2021	SELL	$71.28 - $120.75 $1.25 Million - $2.11 Million	-17,467 Reduced 15.31%	96,591 $7.73 Million
Q4 2020 Feb 12, 2021	BUY	$22.24 - $95.63 $417,511 - $1.8 Million	18,773 Added 19.7%	114,058 $9.31 Million
Q3 2020 Nov 12, 2020	SELL	$19.0 - $30.57 $24,947 - $40,138	-1,313 Reduced 1.36%	95,285 $2.35 Million
Q2 2020 Aug 14, 2020	SELL	$15.26 - $28.66 $25,606 - $48,091	-1,678 Reduced 1.71%	96,598 $2.71 Million
Q1 2020 May 12, 2020	BUY	$13.31 - $29.2 $1.31 Million - $2.87 Million	98,276 New	98,276 $1.77 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Granahan Investment Management, LLC with notifications on news.